Preliminary results from a Phase 1b proof-of-conce
Post# of 148181
(Total Views: 341)
Posted On: 07/22/2019 1:02:16 PM
Preliminary results from a Phase 1b proof-of-concept study assessing a single subcutaneous injection of Gilead Sciences' (GILD -0.2%) HIV capsid function inhibitor GS-6207 in HIV-positive patients showed significant reductions in HIV-1 RNA compared to placebo. The data were presented at the International AIDS Society Conference on HIV Science in Mexico City.
No serious adverse events or discontinuations were reported.
GS-6207 has Breakthrough Therapy status for multidrug-resistant HIV.
Development is ongoing.
No serious adverse events or discontinuations were reported.
GS-6207 has Breakthrough Therapy status for multidrug-resistant HIV.
Development is ongoing.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼